Viridian Therapeutics, Inc.\DE 8-K

What Happened

• On March 30, 2026, Viridian Therapeutics, Inc. announced topline data from its Phase 3 REVEAL-1 trial of elegrobart, a subcutaneously delivered anti–insulin-like growth factor‑1 receptor (IGF‑1R) antibody, in patients with active thyroid eye disease. The company also released an updated corporate presentation that includes the topline data. The press release and presentation were furnished as exhibits to the Form 8-K.

Key Details

• Date of disclosure: March 30, 2026 (8-K Item 7.01, Regulation FD disclosure).
• Therapy: elegrobart — subcutaneous anti–IGF‑1R antibody.
• Trial: Phase 3 REVEAL-1 in active thyroid eye disease; topline results were announced (full data and details included in the company's press release and presentation).
• Exhibits filed with the 8-K: press release and corporate presentation (Exhibits 99.1 and 99.2).

Why It Matters

• Topline Phase 3 results are a major clinical milestone for a development-stage drug and can affect Viridian’s regulatory path, partnering prospects, and investor valuation. The released materials (press release + presentation) are the primary sources for the efficacy, safety, and next-step information investors will use to assess the program. Investors should review the company’s press release and presentation for specific outcome measures, safety data, and planned regulatory or commercial timelines.